Fulvestrant is available in a pre-filled syringe of 250 mg per 5 mL.

**Dosing**

For advanced, hormone receptor-positive breast cancer or hormone receptor-positive HER2-negative breast cancer: 500 mg IM, administered as two 5 mL injections, one in each buttock on days 1, 15, and 29, and subsequently once monthly.

For advanced or metastatic disease: Same dosing as above, in combination with ribociclib. If giving with palbociclib or ademaciclib, administer with an LHRH agonist in pre or perimenopausal patients.

In cases of moderate liver impairment, the recommendation is to reduce the dose to 250 mg.